Table 1 Demographic and clinical characteristics of patients with left ventricular systolic dysfunction and non-left ventricular systolic dysfunction
Non-LVSD group (n = 73) | LVSD group (n = 51) | p | |
|---|---|---|---|
Basic characteristic | |||
Male sex—no. (%) | 49 (67.1%) | 37 (72.5%) | 0.519 |
Age—year | 68 (63,74) | 68 (57,77) | 0.931 |
BMI (kg/m2) | 24.1 (21.6,26.1) | 22.5 (20.1,25.2) | 0.061 |
LV GLS (%) | 17.6 (18.2,19.6) | 15.9 (14.7,16.8) | < 0.001* |
LV EF (%) | 52.1 ± 0.5 | 51.5 ± 0.8 | 0.057 |
Septic shock—no. (%) | 54 (74.0%) | 39(76.5%) | 0.752 |
Underlying medical conditions | |||
Hypertension—no. (%) | 33 (45.2%) | 25 (49.0%) | 0.675 |
Diabetes—no. (%) | 14 (19.2%) | 8 (15.7%) | 0.616 |
Chronic kidney injury—no. (%) | 7 (9.6%) | 4 (7.8%) | 0.737 |
Clinical characteristics | |||
Respiratory rate (bpm) | 24 (20,29) | 22 (20,26) | 0.337 |
Blood pressure (mmHg) | 67.3 (60.7,80) | 73 (63.3,85.7) | 0.217 |
Heart rate (bpm) | 110.3 ± 24.0 | 112.0 ± 25.5 | 0.714 |
Body temperature (℃) | 37.8 ± 0.1 | 37.6 ± 0.1 | 0.476 |
CVP (mmHg) | 8.4 ± 3.8 | 9.9 ± 4.9 | 0.087 |
Organ function score | |||
APACHE II score | 16.0 (12,20) | 17 (14,22) | 0.352 |
SOFA score | 9.6 ± 3.0 | 10.9 ± 3.4 | 0.027* |
Laboratory data | |||
Leucocyte count (109/L) | 11.2 (6.2,19.2) | 9.9 (6.0,17.5) | 0.575 |
Hemoglobin (g/L) | 108.0 ± 27.1 | 105.3 ± 35.9 | 0.853 |
Platelet (109/L) | 160 (104,215) | 134 (89,224) | 0.369 |
Albumin (g/L) | 27.6(23.7,31.4) | 29.7(26.232.8) | 0.188 |
Bilirubin (mmol/L) | 20.2 (12.5,30.9) | 18.8 (13.4,25.8) | 0.455 |
Plasma creatinine (umol/L) | 90.3(62.8,173.5) | 110.2(65.1,178.9) | 0.542 |
PCT (ng/mL) | 3.3 (0.5,21) | 22 (0.7,91) | 0.013 |
Hs-TnI (ng/mL) | 0.04 (0.02,0.12) | 0.27 (0.07,0.86) | < 0.001 |
NT-proBNP (pg/mL) | 1020 (321,3060) | 4560 (1740,9580) | < 0.001 |
pH | 7.34 ± 0.09 | 7.32 ± 0.11 | 0.337 |
Lac (mmol/L) | 2.5 (1.7, 3.8) | 3.7 (2.2, 5.9) | 0.008 |
P(v-a)CO2 > 6 mmHg no. (%) | 27 (61.4%) | 22 (64.7%) | 0.762 |
24-h fluid balance (mL) | 1994.3 ± 159.6 | 1892.1 ± 237.9 | 0.711 |
Vasoactive drugs | |||
VDI (ug/min) | 18 (0,42) | 36 (12,60) | 0.007* |
Inotropic drugs used—no. (%) | 2 (2.8%) | 4 (7.8%) | 0.193 |
Site of infection—no. (%) | |||
Lungs | 20 (27.4%) | 20 (39.2%) | 0.196 |
Blood | 1 (1.4%) | 2 (3.9%) | |
Abdomen | 45 (61.6%) | 21 (41.2%) | |
Soft tissue | 2 (2.7%) | 3 (5.9%) | |
Urinary tract | 2 (2.7%) | 2 (3.9%) | |
Central nervous system | 2 (2.7%) | 0 | |
Others | 1 (1.4%) | 3 (5.9%) | |